A detailed history of D. E. Shaw & Co., Inc. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 138,408 shares of VRTX stock, worth $56.5 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares
138,408
Holding current value
$56.5 Million
% of portfolio
0.06%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$460.0 - $505.78 $14.6 Million - $16 Million
-31,655 Reduced 18.61%
138,408 $64.4 Million
Q2 2024

Aug 14, 2024

SELL
$392.81 - $485.53 $72.8 Million - $90 Million
-185,395 Reduced 52.16%
170,063 $79.7 Million
Q1 2024

May 15, 2024

BUY
$407.69 - $446.08 $58.1 Million - $63.6 Million
142,477 Added 66.9%
355,458 $149 Million
Q4 2023

Feb 14, 2024

SELL
$343.0 - $410.68 $15.1 Million - $18.1 Million
-44,012 Reduced 17.13%
212,981 $86.7 Million
Q3 2023

Nov 14, 2023

BUY
$338.18 - $362.46 $1.77 Million - $1.9 Million
5,235 Added 2.08%
256,993 $89.4 Million
Q2 2023

Aug 14, 2023

BUY
$314.42 - $351.91 $14.7 Million - $16.5 Million
46,826 Added 22.85%
251,758 $88.6 Million
Q1 2023

May 15, 2023

BUY
$283.23 - $323.1 $26.7 Million - $30.5 Million
94,399 Added 85.4%
204,932 $64.6 Million
Q4 2022

Feb 14, 2023

SELL
$285.76 - $321.48 $2.21 Million - $2.48 Million
-7,720 Reduced 6.53%
110,533 $31.9 Million
Q3 2022

Nov 14, 2022

SELL
$273.83 - $305.53 $43.9 Million - $49 Million
-160,491 Reduced 57.58%
118,253 $34.2 Million
Q2 2022

Aug 15, 2022

SELL
$234.96 - $292.55 $109 Million - $136 Million
-465,504 Reduced 62.55%
278,744 $78.5 Million
Q1 2022

May 16, 2022

SELL
$221.42 - $260.97 $61.3 Million - $72.3 Million
-277,075 Reduced 27.13%
744,248 $194 Million
Q4 2021

Feb 14, 2022

SELL
$177.01 - $223.45 $123 Million - $155 Million
-693,311 Reduced 40.43%
1,021,323 $224 Million
Q3 2021

Nov 15, 2021

BUY
$181.39 - $202.99 $170 Million - $190 Million
937,619 Added 120.67%
1,714,634 $311 Million
Q2 2021

Aug 16, 2021

BUY
$187.49 - $221.1 $43.2 Million - $50.9 Million
230,391 Added 42.15%
777,015 $157 Million
Q1 2021

May 17, 2021

SELL
$207.02 - $241.31 $67.8 Million - $79.1 Million
-327,724 Reduced 37.48%
546,624 $117 Million
Q4 2020

Feb 16, 2021

BUY
$207.01 - $276.09 $108 Million - $144 Million
523,210 Added 149.0%
874,348 $207 Million
Q3 2020

Nov 16, 2020

BUY
$255.65 - $303.1 $52 Million - $61.6 Million
203,308 Added 137.53%
351,138 $95.6 Million
Q2 2020

Aug 14, 2020

SELL
$225.48 - $295.8 $33.7 Million - $44.2 Million
-149,357 Reduced 50.26%
147,830 $42.9 Million
Q1 2020

May 15, 2020

SELL
$199.77 - $247.81 $15.3 Million - $19 Million
-76,786 Reduced 20.53%
297,187 $70.7 Million
Q4 2019

Feb 14, 2020

SELL
$166.71 - $223.91 $54.1 Million - $72.7 Million
-324,695 Reduced 46.47%
373,973 $81.9 Million
Q3 2019

Nov 14, 2019

SELL
$166.23 - $187.09 $28.5 Million - $32 Million
-171,241 Reduced 19.68%
698,668 $118 Million
Q2 2019

Aug 14, 2019

SELL
$164.61 - $190.37 $21.9 Million - $25.4 Million
-133,320 Reduced 13.29%
869,909 $160 Million
Q1 2019

May 15, 2019

SELL
$163.73 - $194.7 $27.1 Million - $32.2 Million
-165,372 Reduced 14.15%
1,003,229 $185 Million
Q4 2018

Feb 14, 2019

SELL
$151.91 - $192.21 $14.7 Million - $18.6 Million
-96,755 Reduced 7.65%
1,168,601 $194 Million
Q3 2018

Nov 14, 2018

BUY
$167.73 - $192.74 $27.5 Million - $31.6 Million
163,766 Added 14.87%
1,265,356 $244 Million
Q2 2018

Aug 14, 2018

BUY
$145.72 - $169.96 $20.8 Million - $24.2 Million
142,529 Added 14.86%
1,101,590 $187 Million
Q1 2018

May 15, 2018

BUY
$151.6 - $177.13 $81.8 Million - $95.5 Million
539,411 Added 128.54%
959,061 $156 Million
Q4 2017

Feb 14, 2018

BUY
$137.28 - $155.55 $13.1 Million - $14.9 Million
95,561 Added 29.49%
419,650 $62.9 Million
Q3 2017

Nov 14, 2017

BUY
$148.13 - $162.24 $48 Million - $52.6 Million
324,089
324,089 $49.3 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $105B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track D. E. Shaw & Co., Inc. Portfolio

Follow D. E. Shaw & Co., Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.